Related Experiment Videos
Misoprostol therapeutics revisited
N M Davies1, J Longstreth, F Jamali
1Faculty of Pharmacy, University of Sydney, New South Wales, Australia.
Abstract:
Misoprostol, a prostaglandin E1 analog, is a racemate of four stereoisomers. On administration it rapidly de-esterifies to its active form, misoprostolic acid. Misoprostolic acid is 85% albumin bound and has a half-life of approximately 30 minutes. It is excreted in urine as inactive metabolites. No significant drug interactions have been reported. Besides its gastrointestinal protective and uterotonic activities, misoprostol regulates various immunologic cascades. It inhibits platelet-activating factor and leukocyte adherence, and modulates adhesion molecule expression. It protects against gut irradiation injury, experimental gastric cancer, enteropathy, and constipation. It improves nutrient absorption in cystic fibrosis. Misoprostol has utility in acetaminophen and ethanol hepatotoxicity, hepatitis, and fibrosis. It is effective in asthmatics and aspirin-sensitive asthmatic and allergic patients. It lowers cholesterol and severity of peripheral vascular diseases, prolongs survival of cardiac and kidney transplantation, synergizes cyclosporine, and protects against cyclosporine-induced renal damage. It works against drug-induced renal damage, interstitial cystitis, lupus nephritis, and hepatorenal syndrome. It is useful in periodontal disease and dental repair. Misoprostol enhances glycosoaminoglycan synthesis in cartilage after injury. It prevents ultraviolet-induced cataracts and reduces intraocular pressure in glaucoma and ocular hypertension. It synergizes antiinflammatory and analgesic effects of diclofenac or colchicine and has been administered to treat trigeminal neuralgic pain. It reduces chemotherapy-induced hair loss and recovery time from burn injury, and is effective in treating sepsis, multiple sclerosis, and pancreatitis.
Insights
Misoprostol, a prostaglandin E1 analog, offers broad therapeutic benefits beyond its gastrointestinal and uterotonic effects. This versatile medication demonstrates potential in managing various inflammatory, immunologic, and organ-specific conditions.
Area of Science:
- Pharmacology
- Immunology
- Gastroenterology
Background:
- Misoprostol is a prostaglandin E1 analog rapidly converted to its active form, misoprostolic acid.
- Misoprostolic acid has a short half-life and is excreted as inactive metabolites, with no significant drug interactions reported.
Purpose of the Study:
- To explore the diverse therapeutic applications of misoprostol.
- To highlight its immunomodulatory and organ-protective effects.
Main Methods:
- Review of existing literature on misoprostol's pharmacological actions and clinical uses.
- Analysis of misoprostol's effects on various biological cascades and disease models.
Main Results:
- Misoprostol regulates immunologic cascades, inhibiting platelet-activating factor and leukocyte adherence.
- Demonstrated efficacy in gastrointestinal protection, organ injury (liver, kidney, gut), inflammatory conditions, and post-transplant care.
- Shown to improve nutrient absorption, reduce intraocular pressure, and synergize with other medications.
Conclusions:
- Misoprostol possesses a wide range of therapeutic applications due to its anti-inflammatory and cytoprotective properties.
- Its immunomodulatory actions contribute to its utility in diverse medical conditions, including organ transplantation and autoimmune diseases.